Systems metabolic engineering of Escherichia coli for the heterologous production of high value molecules — a veteran at new shores

Current Opinion in Biotechnology

Volumn 42, Issue , 2016, Pages 178-188

  Becker, Judith ^a   Wittmann, Christoph ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ENGINEERING; ESCHERICHIA COLI; METABOLISM; MOLECULES; PRODUCTION PLATFORMS;

HETEROLOGOUS PRODUCTION; INDUSTRIAL BIOTECHNOLOGY; INTEGRATE SYSTEMS; IS-ENABLED; L-AMINO ACIDS; NUTRACEUTICALS; SYNTHETIC BIOLOGY; SYSTEMS METABOLIC ENGINEERINGS;

METABOLIC ENGINEERING;

2' FUCOSYLLACTOSE; AMORPHADIENE; AROMATIC COMPOUND; ASTAXANTHIN; BETA CAROTENE; CHONDROITIN; CINNAMALDEHYDE; DEOXYVIOLACEIN; DITERPENE; FARNESENE; GLYCOSAMINOGLYCAN POLYSULFATE; HYALURONIC ACID; KAURENE DERIVATIVE; MYRCENE; OLIGOSACCHARIDE; PROTOILLUDENE; RIBOFLAVIN; SALIDROSIDE; SESQUITERPENE; SILK; SPIDER SILK PROTEIN; TAXADIENE; TYROSOL; UNCLASSIFIED DRUG; VIOLACEIN; ZEAXANTHIN; AMINO ACID; BIOLOGICAL PRODUCT;

BACTERIAL CELL; BACTERIAL STRAIN; BIOTECHNOLOGY; CELL COMPARTMENTALIZATION; CELL METABOLISM; ESCHERICHIA COLI; GENE CLUSTER; HETEROLOGOUS EXPRESSION; HUMAN; METABOLIC ENGINEERING; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYNTHESIS; SYNTHETIC BIOLOGY; SYSTEMS BIOLOGY; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; PROCEDURES; TRENDS;

AMINO ACIDS; ANIMALS; BIOLOGICAL PRODUCTS; BIOTECHNOLOGY; ESCHERICHIA COLI; HUMANS; METABOLIC ENGINEERING; SYNTHETIC BIOLOGY; SYSTEMS BIOLOGY;

EID: 84982836684     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2016.05.004     Document Type: Review

References (83)

1. 1 Huang, H.T., Production of L-threonine by auxotrophic mutants of Escherichia coli. Appl Microbiol 9 (1961), 419–424.
2. 2 Riggs, A.D., Bacterial production of human insulin. Diabetes Care 4 (1981), 64–68.
3. 3 Förster, A.H., Gescher, J., Metabolic engineering of Escherichia coli for production of mixed-acid fermentation end products. Front Bioeng Biotechnol, 2, 2014, 16.
4. 4 Richter, K., Gescher, J., The molecular toolbox for chromosomal heterologous multiprotein expression in Escherichia coli. Biochem Soc Trans 40 (2012), 1222–1226.
5. 5 Becker, J., Wittmann, C., Advanced biotechnology metabolically engineered cells for the bio-based production of chemicals and fuels, materials, and health-care products. Angew Chem Int Ed Engl 54 (2015), 3328–3350.
6. 6 Na, D., Park, J.H., Jang, Y.S., Lee, J.W., Lee, S.Y., Systems metabolic engineering of Escherichia coli for chemicals, materials, biofuels, and pharmaceuticals. Wittmann, C, Lee, S.Y., (eds.) Systems Metabolic Engineering, 2012, Springer, 117–149.
7. 7 Wang, J., Guleria, S., Koffas, M.A., Yan, Y., Microbial production of value-added nutraceuticals. Curr Opin Biotechnol 37 (2015), 97–104.
8. 8 Dai, Z., Nielsen, J., Advancing metabolic engineering through systems biology of industrial microorganisms. Curr Opin Biotechnol 36 (2015), 8–15.
9. 9 Tuli, H.S., Chaudhary, P., Beniwal, V., Sharma, A.K., Microbial pigments as natural color sources: current trends and future perspectives. J Food Sci Technol 52 (2015), 4669–4678.
10. 10•• Rodrigues, A.L., Becker, J., de Souza Lima, A.O., Porto, L.M., Wittmann, C., Systems metabolic engineering of Escherichia coli for gram scale production of the antitumor drug deoxyviolacein from glycerol. Biotechnol Bioeng 111 (2014), 2280–2289 This paper reports on the heterologous production of the high-value therapeutic agent deoxyviolacein with an outstanding production titer of 1.6 g/L. The heart of the study is a tailor-made E. coli strain, which was engineered on a systems-wide level. Optimized process operations and streamlined purification yielded >99.5% pure deoxyviolacein.
11. 11 Rodrigues, A.L., Göcke, Y., Bolten, C., Brock, N.L., Dickschat, J.S., Wittmann, C., Microbial production of the drugs violacein and deoxyviolacein: analytical development and strain comparison. Biotechnol Lett 34 (2012), 717–720.
12. 12 Rodrigues, A.L., Trachtmann, N., Becker, J., Lohanatha, A.F., Blotenberg, J., Bolten, C.J., Korneli, C., de Souza Lima, A.O., Porto, L.M., Sprenger, G.A., Wittmann, C., Systems metabolic engineering of Escherichia coli for production of the antitumor drugs violacein and deoxyviolacein. Metab Eng 20 (2013), 29–41.
13. 13 Fang, M.Y., Zhang, C., Yang, S., Cui, J.Y., Jiang, P.X., Lou, K., Wachi, M., Xing, X.H., High crude violacein production from glucose by Escherichia coli engineered with interactive control of tryptophan pathway and violacein biosynthetic pathway. Microb Cell Fact, 14, 2015, 8.
14. 14 Jones, J.A., Vernacchio, V.R., Lachance, D.M., Lebovich, M., Fu, L., Shirke, A.N., Schultz, V.L., Cress, B., Linhardt, R.J., Koffas, M.A., ePathOptimize: a combinatorial approach for transcriptional balancing of metabolic pathways. Sci Rep, 5, 2015, 11301.
15. 15 Schwechheimer, S.K., Park, E.Y., Revuelta, J.L., Becker, J., Wittmann, C., Biotechnology of riboflavin. Appl Microbiol Biotechnol, 2016.
16. 16 Stahmann, K.P., Revuelta, J.L., Seulberger, H., Three biotechnical processes using Ashbya gossypii, Candida famata, or Bacillus subtilis compete with chemical riboflavin production. Appl Microbiol Biotechnol 53 (2000), 509–516.
17. 17 Kato, T., Park, E.Y., Riboflavin production by Ashbya gossypii. Biotechnol Lett 34 (2012), 611–618.
18. 18 Lin, Z., Xu, Z., Li, Y., Wang, Z., Chen, T., Zhao, X., Metabolic engineering of Escherichia coli for the production of riboflavin. Microb Cell Fact, 13, 2014, 104.
19. 19 Becker, J., Klopprogge, C., Herold, A., Zelder, O., Bolten, C.J., Wittmann, C., Metabolic flux engineering of L-lysine production in Corynebacterium glutamicum — over expression and modification of G6P dehydrogenase. J Biotechnol 132 (2007), 99–109.
20. 20 Ohnishi, J., Katahira, R., Mitsuhashi, S., Kakita, S., Ikeda, M., A novel gnd mutation leading to increased L-lysine production in Corynebacterium glutamicum. FEMS Microbiol Lett 242 (2005), 265–274.
21. 21 Nabavi, S.F., Braidy, N., Orhan, I.E., Badiee, A., Daglia, M., Nabavi, S.M., Rhodiola rosea L. and Alzheimer's disease: from farm to pharmacy. Phytother Res 30 (2016), 532–539.
22. 22 Bai, Y., Bi, H., Zhuang, Y., Liu, C., Cai, T., Liu, X., Zhang, X., Liu, T., Ma, Y., Production of salidroside in metabolically engineered Escherichia coli. Sci Rep, 4, 2014, 6640.
23. 23 Jiang, M., Zhang, H., Engineering the shikimate pathway for biosynthesis of molecules with pharmaceutical activities in E. coli. Curr Opin Biotechnol 42 (2016), 1–6.
24. 24 Luo, Y., Li, B.Z., Liu, D., Zhang, L., Chen, Y., Jia, B., Zeng, B.X., Zhao, H., Yuan, Y.J., Engineered biosynthesis of natural products in heterologous hosts. Chem Soc Rev, 2015, 5265–5290.
25. 25 Rufino, A.T., Ribeiro, M., Sousa, C., Judas, F., Salgueiro, L., Cavaleiro, C., Mendes, A.F., Evaluation of the anti-inflammatory, anti-catabolic and pro-anabolic effects of E-caryophyllene, myrcene and limonene in a cell model of osteoarthritis. Eur J Pharmacol 750 (2015), 141–150.
26. 26 Kim, E.M., Eom, J.H., Um, Y., Kim, Y., Woo, H.M., Microbial synthesis of myrcene by metabolically engineered Escherichia coli. J Agric Food Chem 63 (2015), 4606–4612.
27. 27 Paddon, C.J., Keasling, J.D., Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development. Nat Rev Microbiol 12 (2014), 355–367.
28. 28 Martin, V.J., Pitera, D.J., Withers, S.T., Newman, J.D., Keasling, J.D., Engineering a mevalonate pathway in Escherichia coli for production of terpenoids. Nat Biotechnol 21 (2003), 796–802.
29. 29•• Tsuruta, H., Paddon, C.J., Eng, D., Lenihan, J.R., Horning, T., Anthony, L.C., Regentin, R., Keasling, J.D., Renninger, N.S., Newman, J.D., High-level production of amorpha-4,11-diene, a precursor of the antimalarial agent artemisinin, in Escherichia coli. PLoS One, 4, 2009, e4489 This study is the first report on the production of the artemisinin precursor amorpha-4,11-diene at commercially relevant titers. Production performance of the recombinant strains was substantially optimized by selecting the most suitable enzyme variants for S. cerevisiae and S. aureus. Combined with a superior fermentation process, 27.4 g/L amorpha-4,11-diene was produced in fed-batch fermentation.
30. 30 Zhang, C., Zou, R., Chen, X., Stephanopoulos, G., Too, H.P., Experimental design-aided systematic pathway optimization of glucose uptake and deoxyxylulose phosphate pathway for improved amorphadiene production. Appl Microbiol Biotechnol 99 (2015), 3825–3837.
31. 31 Paddon, C.J., Westfall, P.J., Pitera, D.J., Benjamin, K., Fisher, K., McPhee, D., Leavell, M.D., Tai, A., Main, A., Eng, D., Polichuk, D.R., Teoh, K.H., Reed, D.W., Treynor, T., Lenihan, J., Fleck, M., Bajad, S., Dang, G., Dengrove, D., Diola, D., Dorin, G., Ellens, K.W., Fickes, S., Galazzo, J., Gaucher, S.P., Geistlinger, T., Henry, R., Hepp, M., Horning, T., Iqbal, T., Jiang, H., Kizer, L., Lieu, B., Melis, D., Moss, N., Regentin, R., Secrest, S., Tsuruta, H., Vazquez, R., Westblade, L.F., Xu, L., Yu, M., Zhang, Y., Zhao, L., Lievense, J., Covello, P.S., Keasling, J.D., Reiling, K.K., Renninger, N.S., Newman, J.D., High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 496 (2013), 528–532.
32. 32 Leavell, M.D., McPhee, D.J., Paddon, C.J., Developing fermentative terpenoid production for commercial usage. Curr Opin Biotechnol 37 (2015), 114–119.
33. 33 Yang, L., Wang, C., Zhou, J., Kim, S.W., Combinatorial engineering of hybrid mevalonate pathways in Escherichia coli for protoilludene production. Microb Cell Fact, 15, 2016, 14.
34. 34 Soliman, S., Tang, Y., Natural and engineered production of taxadiene with taxadiene synthase. Biotechnol Bioeng 112 (2015), 229–235.
35. 35 Trosset, J.Y., Carbonell, P., Synthetic biology for pharmaceutical drug discovery. Drug Des Devel Ther 9 (2015), 6285–6302.
36. 36 Howat, S., Park, B., Oh, I.S., Jin, Y.W., Lee, E.K., Loake, G.J., Paclitaxel: biosynthesis, production and future prospects. Nat Biotechnol 31 (2014), 242–245.
37. 37 Ajikumar, P.K., Xiao, W.H., Tyo, K.E., Wang, Y., Simeon, F., Leonard, E., Mucha, O., Phon, T.H., Pfeifer, B., Stephanopoulos, G., Isoprenoid pathway optimization for Taxol precursor overproduction in Escherichia coli. Science 330 (2010), 70–74.
38. 38 Dejong, J.M., Liu, Y., Bollon, A.P., Long, R.M., Jennewein, S., Williams, D., Croteau, R.B., Genetic engineering of taxol biosynthetic genes in Saccharomyces cerevisiae. Biotechnol Bioeng 93 (2006), 212–224.
39. 39 Huang, Q., Roessner, C.A., Croteau, R., Scott, A.I., Engineering Escherichia coli for the synthesis of taxadiene, a key intermediate in the biosynthesis of taxol. Bioorg Med Chem 9 (2001), 2237–2242.
40. 40• Zhou, K., Qiao, K., Edgar, S., Stephanopoulos, G., Distributing a metabolic pathway among a microbial consortium enhances production of natural products. Nat Biotechnol 33 (2015), 377–383 This study proposes a promising concept to link the synthetic capacity of different cells for production.
41. 41 Alper, H., Jin, Y.S., Moxley, J.F., Stephanopoulos, G., Identifying gene targets for the metabolic engineering of lycopene biosynthesis in Escherichia coli. Metab Eng 7 (2005), 155–164.
42. 42 Alper, H., Miyaoku, K., Stephanopoulos, G., Construction of lycopene-overproducing E. coli strains by combining systematic and combinatorial gene knockout targets. Nat Biotechnol 23 (2005), 612–616.
43. 43• Zhao, J., Li, Q., Sun, T., Zhu, X., Xu, H., Tang, J., Zhang, X., Ma, Y., Engineering central metabolic modules of Escherichia coli for improving beta-carotene production. Metab Eng 17 (2013), 42–50 Authors applied a multi-module combinatory approach to optimize beta-carotene production in E. coli. Variations in the expression levels of selected genes from the TCA cycle, PP pathway, ATP synthesis, isoprenoid pathway, and terminal biosynthesis allowed the production of 2.1 g/L beta-carotene.
44. 44 Lemuth, K., Steuer, K., Albermann, C., Engineering of a plasmid-free Escherichia coli strain for improved in vivo biosynthesis of astaxanthin. Microb Cell Fact, 10, 2011, 29.
45. 45 Li, X.R., Tian, G.Q., Shen, H.J., Liu, J.Z., Metabolic engineering of Escherichia coli to produce zeaxanthin. J Ind Microbiol Biotechnol 42 (2015), 627–636.
46. 46 Weichert, S., Jennewein, S., Hufner, E., Weiss, C., Borkowski, J., Putze, J., Schroten, H., Bioengineered 2′-fucosyllactose and 3-fucosyllactose inhibit the adhesion of Pseudomonas aeruginosa and enteric pathogens to human intestinal and respiratory cell lines. Nutr Res 33 (2013), 831–838.
47. 47 Chin, Y.W., Kim, J.Y., Lee, W.H., Seo, J.H., Enhanced production of 2′-fucosyllactose in engineered Escherichia coli BL21star(DE3) by modulation of lactose metabolism and fucosyltransferase. J Biotechnol 210 (2015), 107–115.
48. 48• Baumgärtner, F., Seitz, L., Sprenger, G.A., Albermann, C., Construction of Escherichia coli strains with chromosomally integrated expression cassettes for the synthesis of 2′-fucosyllactose. Microb Cell Fact, 12, 2013, 40 The authors constructed the first selection of a marker-free E. coli strain that produces 2′-fucosyllactose from lactose and glycerol. Implementation of the full biosynthetic pathway for GDP-L-fucose allowed de novo synthesis of the high-priced fucose component from glycerol. Overall, a final 2′-fucosyllactose concentration of >20 g/L was achieved.
49. 49 Lee, W.H., Pathanibul, P., Quarterman, J., Jo, J.H., Han, N.S., Miller, M.J., Jin, Y.S., Seo, J.H., Whole cell biosynthesis of a functional oligosaccharide, 2′-fucosyllactose, using engineered Escherichia coli. Microb Cell Fact, 11, 2012, 48.
50. 50 Baumgärtner, F., Conrad, J., Sprenger, G.A., Albermann, C., Synthesis of the human milk oligosaccharide lacto-N-tetraose in metabolically engineered, plasmid-free E. coli. Chembiochem 15 (2014), 1896–1900.
51. 51 Baumgärtner, F., Jurzitza, L., Conrad, J., Beifuss, U., Sprenger, G.A., Albermann, C., Synthesis of fucosylated lacto-N-tetraose using whole-cell biotransformation. Bioorg Med Chem 23 (2015), 6799–6806.
52. 52 Lezyk, M., Jers, C., Kjaerulff, L., Gotfredsen, C.H., Mikkelsen, M.D., Mikkelsen, J.D., Novel alpha-L-fucosidases from a soil metagenome for production of fucosylated human milk oligosaccharides. PLOS ONE, 11, 2016, e0147438.
53. 53 Pena, C., Castillo, T., Garcia, A., Millan, M., Segura, D., Biotechnological strategies to improve production of microbial poly-(3-hydroxybutyrate): a review of recent research work. Microb Biotechnol 7 (2014), 278–293.
54. 54 Becker, J., Wittmann, C., Diamines for bio-based materials. Wittmann, C., Liao, J.C., (eds.) Industrial Biotechnology, 2016, Wiley-VCH [in press].
55. 55 Chae, T.U., Kim, W.J., Choi, S., Park, S.J., Lee, S.Y., Metabolic engineering of Escherichia coli for the production of 1,3-diaminopropane, a three carbon diamine. Sci Rep, 5, 2015, 13040.
56. 56 Becker, J., Lange, A., Fabarius, J., Wittmann, C., Top value platform chemicals: bio-based production of organic acids. Curr Opin Biotechnol 36 (2015), 168–175.
57. 57•• Xia, X.X., Qian, Z.G., Ki, C.S., Park, Y.H., Kaplan, D.L., Lee, S.Y., Native-sized recombinant spider silk protein produced in metabolically engineered Escherichia coli results in a strong fiber. Proc Natl Acad Sci U S A 107 (2010), 14059–14063 In this study, E. coli was, for the first time, engineered to produce spider dragline silk, an extraordinarily strong and elastic protein fiber with broad application potential. Strain optimization, high cell density cultivation and subsequent product purification yielded a total of 1.2 g of protein.
58. 58 Xu, M., Lewis, R.V., Structure of a protein superfiber: spider dragline silk. Proc Natl Acad Sci U S A 87 (1990), 7120–7124.
59. 59 Sponner, A., Schlott, B., Vollrath, F., Unger, E., Grosse, F., Weisshart, K., Characterization of the protein components of Nephila clavipes dragline silk. Biochemistry 44 (2005), 4727–4736.
60. 60 Zhang, C., Liu, L., Teng, L., Chen, J., Liu, J., Li, J., Du, G., Metabolic engineering of Escherichia coli BL21 for biosynthesis of heparosan, a bioengineered heparin precursor. Metab Eng 14 (2012), 521–527.
61. 61 Restaino, O.F., Bhaskar, U., Paul, P., Li, L., De Rosa, M., Dordick, J.S., Linhardt, R.J., High cell density cultivation of a recombinant E. coli strain expressing a key enzyme in bioengineered heparin production. Appl Microbiol Biotechnol 97 (2013), 3893–3900.
62. 62 Barreteau, H., Richard, E., Drouillard, S., Samain, E., Priem, B., Production of intracellular heparosan and derived oligosaccharides by lyase expression in metabolically engineered E. coli K-12. Carbohydr Res 360 (2012), 19–24.
63. 63 Yu, H., Tyo, K., Alper, H., Klein-Marcuschamer, D., Stephanopoulos, G., A high-throughput screen for hyaluronic acid accumulation in recombinant Escherichia coli transformed by libraries of engineered sigma factors. Biotechnol Bioeng 101 (2008), 788–796.
64. 64 Yu, H., Stephanopoulos, G., Metabolic engineering of Escherichia coli for biosynthesis of hyaluronic acid. Metab Eng 10 (2008), 24–32.
65. 65 Schiraldi, C., Cimini, D., De Rosa, M., Production of chondroitin sulfate and chondroitin. Appl Microbiol Biotechnol 87 (2010), 1209–1220.
66. 66 Zanfardino, A., Restaino, O.F., Notomista, E., Cimini, D., Schiraldi, C., De Rosa, M., De Felice, M., Varcamonti, M., Isolation of an Escherichia coli K4 kfoC mutant over-producing capsular chondroitin. Microb Cell Fact, 9, 2010, 34.
67. 67 Cimini, D., De Rosa, M., Viggiani, A., Restaino, O.F., Carlino, E., Schiraldi, C., Improved fructosylated chondroitin production by kfoC overexpression in E. coli K4. J Biotechnol 150 (2010), 324–331.
68. 68 Cimini, D., Fantaccione, S., Volpe, F., De Rosa, M., Restaino, O.F., Aquino, G., Schiraldi, C., IS2-mediated overexpression of kfoC in E. coli K4 increases chondroitin-like capsular polysaccharide production. Appl Microbiol Biotechnol 98 (2014), 3955–3964.
69. 69 He, W., Fu, L., Li, G., Andrew Jones, J., Linhardt, R.J., Koffas, M., Production of chondroitin in metabolically engineered E. coli. Metab Eng 27 (2015), 92–100.
70. 70 Becker, J., Wittmann, C., Systems and synthetic metabolic engineering for amino acid production — the heartbeat of industrial strain development. Curr Opin Biotechnol 23 (2012), 718–726.
71. 71 Becker, J., Wittmann, C., Bio-based production of chemicals, materials and fuels — Corynebacterium glutamicum as versatile cell factory. Curr Opin Biotechnol 23 (2012), 631–640.
72. 72 Heider, S.A., Wendisch, V.F., Engineering microbial cell factories: metabolic engineering of Corynebacterium glutamicum with a focus on non-natural products. Biotechnol J 10 (2015), 1170–1184.
73. 73 Liu, L., Redden, H., Alper, H.S., Frontiers of yeast metabolic engineering: diversifying beyond ethanol and Saccharomyces. Curr Opin Biotechnol 24 (2013), 1023–1030.
74. 74 Gosset, G., Production of aromatic compounds in bacteria. Curr Opin Biotechnol 20 (2009), 651–658.
75. 75 Kaneko, M., Hwang, E.I., Ohnishi, Y., Horinouchi, S., Heterologous production of flavanones in Escherichia coli: potential for combinatorial biosynthesis of flavonoids in bacteria. J Ind Microbiol Biotechnol 30 (2003), 456–461.
76. 76 Yang, S.M., Shim, G.Y., Kim, B.G., Ahn, J.H., Biological synthesis of coumarins in Escherichia coli. Microb Cell Fact, 14, 2015, 65.
77. 77 Chen, Y., Zhou, Y.J., Siewers, V., Nielsen, J., Enabling technologies to advance microbial isoprenoid production. Adv Biochem Eng Biotechnol 148 (2015), 143–160.
78. 78 Kong, M.K., Kang, H.J., Kim, J.H., Oh, S.H., Lee, P.C., Metabolic engineering of the Stevia rebaudiana ent-kaurene biosynthetic pathway in recombinant Escherichia coli. J Biotechnol 214 (2015), 95–102.
79. 79 Bang, H.B., Lee, Y.H., Kim, S.C., Sung, C.K., Jeong, K.J., Metabolic engineering of Escherichia coli for the production of cinnamaldehyde. Microb Cell Fact, 15, 2016, 16.
80. 80 Zhu, F., Zhong, X., Hu, M., Lu, L., Deng, Z., Liu, T., In vitro reconstitution of mevalonate pathway and targeted engineering of farnesene overproduction in Escherichia coli. Biotechnol Bioeng 111 (2014), 1396–1405.
81. 81 Avalos, J.L., Fink, G.R., Stephanopoulos, G., Compartmentalization of metabolic pathways in yeast mitochondria improves the production of branched-chain alcohols. Nat Biotechnol 31 (2013), 335–341.
82. 82 Huber, M.C., Schreiber, A., von Olshausen, P., Varga, B.R., Kretz, O., Joch, B., Barnert, S., Schubert, R., Eimer, S., Kele, P., Schiller, S.M., Designer amphiphilic proteins as building blocks for the intracellular formation of organelle-like compartments. Nat Mater 14 (2015), 125–132.
83. 83 Poust, S., Hagen, A., Katz, L., Keasling, J.D., Narrowing the gap between the promise and reality of polyketide synthases as a synthetic biology platform. Curr Opin Biotechnol 30 (2014), 32–39.